{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T15:31:31Z","timestamp":1659108691661},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"38","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1097\/md.0000000000007839","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T19:01:16Z","timestamp":1505847676000},"page":"e7839","source":"Crossref","is-referenced-by-count":3,"title":["Five years experience on 3,4-diaminopyridine phosphate in Lambert\u2013Eaton syndrome"],"prefix":"10.1097","volume":"96","author":[{"given":"Simona","family":"Portaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Brizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Sinicropi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Cacciola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina","family":"De Cola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Bramanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demetrio","family":"Milardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonino","family":"Lupica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Placido","family":"Bramanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Toscano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Rodolico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-7-20210226","doi-asserted-by":"crossref","first-page":"293","DOI":"10.12998\/wjcc.v3.i3.293","article-title":"Voltage gated calcium channel antibody-related neurological diseases","volume":"3","author":"Bekircan-Kurt","year":"2015","journal-title":"World J Clin Cases"},{"key":"R2-7-20210226","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF03020488","article-title":"Calcium channels\u2013basic aspects of their structure, function and gene encoding; anesthetic action on the channels-a review","volume":"49","author":"Yamakage","year":"2002","journal-title":"Can J Anaesth"},{"key":"R3-7-20210226","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40120-015-0034-0","article-title":"The European LEMS Registry: baseline demographics and treatment approaches","volume":"4","author":"Mantegazza","year":"2015","journal-title":"Neurol Ther"},{"key":"R4-7-20210226","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","article-title":"Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes","volume":"332","author":"Lennon","year":"1995","journal-title":"N Engl J Med"},{"key":"R5-7-20210226","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/pgmj.75.887.516","article-title":"Lambert-Eaton myasthenic syndrome","volume":"75","author":"Seneviratne","year":"1999","journal-title":"Postgrad Med J"},{"key":"R7-7-20210226","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1196\/annals.1254.065","article-title":"Lambert-eaton myasthenic syndrome: diagnosis and treatment","volume":"998","author":"Sanders","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"R8-7-20210226","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/jnnp.50.4.476","article-title":"Congenital Lambert-Eaton myasthenic syndrome","volume":"50","author":"Bady","year":"1987","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R9-7-20210226","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1212\/WNL.24.9.897","article-title":"Unusual myasthenic state in a teen-age boy","volume":"24","author":"Dahl","year":"1974","journal-title":"Neurology"},{"key":"R10-7-20210226","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1469-8749.1974.tb04187.x","article-title":"A myasthenic syndrome in childhood leukemia","volume":"16","author":"Shapira","year":"1974","journal-title":"Dev Med Child Neurol"},{"key":"R11-7-20210226","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/archneur.1979.00500450066013","article-title":"Eaton-Lambert syndrome in a 9-year-old girl","volume":"36","author":"Chelmicka-Schorr","year":"1979","journal-title":"Arch Neurol"},{"key":"R12-7-20210226","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/mus.880180707","article-title":"Lambert-Eaton myasthenic syndrome (LEMS) in association with lymphoproliferative disorders","volume":"18","author":"Argov","year":"1995","journal-title":"Muscle Nerve"},{"key":"R13-7-20210226","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/088307380201700123","article-title":"Lambert-Eaton myasthenic syndrome in children","volume":"17","author":"Tsao","year":"2002","journal-title":"J Child Neurol"},{"key":"R14-7-20210226","doi-asserted-by":"crossref","first-page":"N58","DOI":"10.1177\/0883073813499970","article-title":"Long-term follow-up in infantile-onset lambert-eaton myasthenic syndrome","volume":"29","author":"Portaro","year":"2014","journal-title":"J Child Neurol"},{"key":"R15-7-20210226","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3111\/13696998.2012.660897","article-title":"Long-term disease history, clinical symptoms, health status, and healthcare utilization in patients suffering from Lambert\u2013Eaton myasthenic syndrome: Results of a patient interview survey in Germany","volume":"15","author":"Harms","year":"2012","journal-title":"J Med Econ"},{"key":"R16-7-20210226","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1749-6632.1971.tb30750.x","article-title":"Quantal components of end-plate potentials in the myasthenic syndrome","volume":"183","author":"Lambert","year":"1971","journal-title":"Ann N Y Acad Sci"},{"key":"R17-7-20210226","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0035-3787(04)70888-7","article-title":"Lambert-Eaton myasthenic syndrome","volume":"160","author":"Newsom-Davis","year":"2004","journal-title":"Rev Neurol (Paris"},{"key":"R18-7-20210226","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0140-6736(81)90474-8","article-title":"Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome","volume":"2","author":"Lang","year":"1981","journal-title":"Lancet"},{"key":"R19-7-20210226","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1212\/WNL.34.4.480","article-title":"Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome","volume":"34","author":"Newsom-Davis","year":"1984","journal-title":"Neurology"},{"key":"R21-7-20210226","first-page":"181","article-title":"Neuromuscular junction channelopathies: a brief overview","volume":"105","author":"Newsom-Davis","year":"2005","journal-title":"Acta Neurol Belg"},{"key":"R22-7-20210226","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1590\/S0004-282X2010000600004","article-title":"Nonparaneoplastic Lambert-Eaton myasthenic syndrome: a brief review of 10 cases","volume":"68","author":"Lorenzoni","year":"2010","journal-title":"Arq Neuro-psiquiatr"},{"key":"R23-7-20210226","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/jnnp.58.1.85","article-title":"An improved diagnostic assay for Lambert-Eaton myasthenic syndrome","volume":"58","author":"Motomura","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R24-7-20210226","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10072-014-1637-4","article-title":"Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management","volume":"35","author":"Evoli","year":"2014","journal-title":"Neurol Sci"},{"key":"R25-7-20210226","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/mus.1140","article-title":"American Association of Electrodiagnostic Medicine. Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electro-diagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome.","volume":"24","year":"2001","journal-title":"Muscle Nerve"},{"key":"R26-7-20210226","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/mus.1139","article-title":"Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement.","volume":"24","year":"2001","journal-title":"Muscle Nerve"},{"key":"R28-7-20210226","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0303-8467(02)00054-9","article-title":"Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases","volume":"104","author":"Wirtz","year":"2002","journal-title":"Clin Neurol Neurosurg"},{"key":"R29-7-20210226","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/clpt.2009.35","article-title":"Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study","volume":"86","author":"Wirtz","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"R30-7-20210226","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0920-1211(92)90016-M","article-title":"Effects of anticonvulsant drugs on 4-aminopyridine-induced seizures in mice","volume":"11","author":"Yamaguchi","year":"1992","journal-title":"Epilepsy Res"},{"key":"R31-7-20210226","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/WNL.31.3.265","article-title":"Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission","volume":"31","author":"Murray","year":"1981","journal-title":"Neurology"},{"key":"R32-7-20210226","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/BF00386054","article-title":"Improvement in neuromuscular transmission in myasthenia gravis by 3,4-diaminopyridine","volume":"234","author":"Lundh","year":"1985","journal-title":"Eur Arch Psychiatry Neurol Sci"},{"key":"R33-7-20210226","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","article-title":"3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome","volume":"321","author":"McEvoy","year":"1989","journal-title":"N Engl J Med"},{"key":"R34-7-20210226","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.54.3.603","article-title":"A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome","volume":"54","author":"Sanders","year":"2000","journal-title":"Neurology"},{"key":"R35-7-20210226","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1185\/03007991003745209","article-title":"Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment","volume":"26","author":"Quartel","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"R36-7-20210226","first-page":"421","article-title":"Lambert-Eaton myasthenic syndrome (LEMS): epidemiology and therapeutic response in the national Veterans Affairs (VA) population","volume":"53","author":"Abenroth","year":"2016","journal-title":"Muscle Nerve"},{"key":"R37-7-20210226","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1200\/JCO.2010.32.0440","article-title":"Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS","volume":"29","author":"Titulaer","year":"2011","journal-title":"J Clin Oncol"},{"key":"R39-7-20210226","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/mus.21422","article-title":"3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS","volume":"40","author":"Oh","year":"2009","journal-title":"Muscle Nerve"},{"key":"R40-7-20210226","first-page":"76","article-title":"A case of Lambert-Eaton myasthenic syndrome with small cell lung cancer, treated with 3,4-diaminopyridine","volume":"47","author":"Uekita","year":"2009","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"R41-7-20210226","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2710.2011.01249.x","article-title":"Content variability of active drug substance in compounded oral 3,4-diaminopyridine products","volume":"37","author":"Green","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"R42-7-20210226","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/mus.25070","article-title":"Amifampridine phosphate (Firdapse(\u00ae)) is effective and safe in a phase 3 clinical trial in LEMS","volume":"53","author":"Oh","year":"2016","journal-title":"Muscle Nerve"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000007839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:57:33Z","timestamp":1620961053000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201709220-00007"}},"subtitle":["Case reports"],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":38,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000007839","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}